Status:
UNKNOWN
The Effects of Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention
Lead Sponsor:
Jordan Hospital
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
* The purpose of this study is to examine the effects of tirofiban on platelet function the Ultegra RPFA in diabetic patients undergoing elective coronary angioplasty and stenting already treated with...
Detailed Description
Introduction Diabetes is a major risk factor for coronary artery disease and diabetic patients are considered CAD equivalent in the absence of CAD1. The presence of CAD and diabetes makes the patient ...
Eligibility Criteria
Inclusion
- Diabetic patients with coronary artery disease undergoing elective percutaneous coronary intervention
Exclusion
- Ongoing ST-segment elevation myocardial infarction (MI)
- Administration of abciximab during the previous two weeks
- Serum creatinine more than 2.5 mg/dl (221 micro-mol/L)
- Ongoing bleeding or bleeding diathesis
- Previous stroke in the last six months
- Major surgery within the previous six weeks
- Platelet count \<100.000 per cubic mm
- Subjects who received low-molecular-weight heparin, tirofiban, or eptifibatide within the 10 hours prior to randomization
- Subjects on oral anticoagulation medication (coumarin derivatives) within the last 7 days unless PT-INR \<1.5 times the control
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00407771
Start Date
November 1 2007
End Date
December 1 2008
Last Update
October 31 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jordan Hospital
Amman, Jordan, 11152